Ganetespib_888216-25-9_CoA_MedChemExpress
Ganetespib_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:Ganetespib is a unique non–geldanamycin heat shock protein 90 (HSP90) inhibitor, with IC 50 of 4 nM in OSA 8 cells.In Vitro: Ganetespib causes depletion of receptor tyrosine kinases, extinguishing of downstream signaling, inhibition of proliferation and induction of apoptosis with IC 50 values ranging 2–30 nM in genomically–defined NSCLC cell lines. Ganetespib is alsoapproximately 20–fold more potent in isogenic Ba/F3 pro–B cells rendered IL–3 independent by expression of EGFR and ERBB2mutants [1]. Ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, induces the degradation of known Hsp90 client proteins, displays superior potency to the ansamycin inhibitor17–allylamino–17–demethoxygeldanamycin (17–AAG)[2]. Ganetespib is a potent HSP90 inhibitor, and shown to kill canine tumor cell lines in vitro [3]. Ganetespib possesses superior JAK/STAT inhibitory activity to both P6 and 17–AAG in terms of potency or duration of response in the HEL92.1.7 cells [4].In Vivo: Ganetespib (125 mg/kg, i.v.) accumulates in tumors relative to normal tissues and displays greater in vivo efficacy than 17–AAG without increased toxicity and inhibits proliferation and induces apoptosis in parallel with EGFR depletion in NCI–H1975xenografts [1]. Ganetespib (100, 125, 150 mg/kg, i.v.) shows potent antitumor efficacy in solid and hematologic xenograft models ofoncogene addiction, as evidenced by significant growth inhibition and/or regressions [2].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Exponentially growing cells are processed in lysis buffer (20 mM HEPES, pH 7.4, 1 mM EDTA, 5 mM MgCl 2, 100 mM KCl) and incubated with increasing concentrations of 17–AAG or ganetespib for 30 min at 4°C, and incubated with biotin–GM linked to Dynabeads MyOne Streptavidin T1 magnetic beads for 1 h at 4°C. Beads are washed three times in lysis buffer and heated for 5 min at 95°C in SDS–PAGE sample buffer. Samples are resolved on 4–12% Bis–Tris gradient gel and Western blots are performed using an anti–HSP90 antibody.Cell Assay:[2]Cells are grown in 96–well plates based on optimal growth rates determined empirically for each line. Twenty–four hours after plating, cells are treated with the indicated compounds or controls for 72 hours. AlamarBlue is added (10% v/v) to the cells, and the plates are incubated for 3 hours and, then, subjected to fluorescence detection. For the comparative viability/apoptosis assay,NCI–H1975 cells are treated with escalating concentrations of ganetespib for the indicated time periods and subjected to viability analysis via CellTiter Fluor and apoptosis via Caspase Glo 3/7.Animal Administration: Ganetespib is formulated in 10/18 DRD (10% DMSO, 18% Cremophor RH 40, 3.6% dextrose and68.4% water).[1]NCI–H1975 or HCC827 cells are cultured as above and 0.5–1×107 cells are mixed with 50% RPMI 1640/50%Matrigel and subcutaneously injected into the flanks of SCID mice. For efficacy studies, animals with 100–200 mm 3 tumors are then randomized into treatments groups of eight. Tumor volumes (V) are calculated by the equation V=0.5236×L×W×T (Length, width, and thickness). Animals are treated by intravenous bolus tail vein injection at 10 mL/kg with ganetespib formulated in 10/18 DRD (10%DMSO, 18% Cremophor RH 40, 3.6% dextrose and 68.4% water). As a measurement of in vivo efficacy, the relative size of treated andProduct Name:Ganetespib Cat. No.:HY-15205CAS No.:888216-25-9Molecular Formula:C 20H 20N 4O 3Molecular Weight:364.40Target:HSP; HSP Pathway:Metabolic Enzyme/Protease; Cell Cycle/DNA Damage Solubility:DMSO: ≥ 32 mg/mLcontrol tumors [(%T/C) value] is determined from the change in average tumor volumes of each drug–treated group relative to the vehicle–treated group, or itself in the case of tumor regression. Body weights are monitored daily. For biomarker studies, mice bearing NCI–H1975 xenografts are treated with either a single dose of vehicle or ganetespib, or with 5 daily doses of vehicle or ganetespib, in groups of 3 or 8, and harvested at various time points. Tumors are excised and flash frozen in liquid nitrogen for preparation of protein lysates or fixed in 10% neutral buffered formalin for immunohistochemistry.References:[1]. Shimamura T, et al. Ganetespib (STA–9090), a Non–Geldanamycin HSP90 Inhibitor, has Potent Antitumor Activity in In Vitro and In Vivo Models ofNon–Small Cell Lung Cancer. Clin Cancer Res. 2012 Jul 17.[2]. Ying W, et al. Ganetespib, a unique triazolone–containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012 Feb;11(2):475–84.[3]. London CA, et al. Phase I evaluation of STA–1474, a prodrug of the novel HSP90 inhibitor ganetespib, in dogs with spontaneous cancer. PLoS One. 2011; 6(11):e27018.[4]. Proia DA, et al. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA–9090) in cancer cells with activated JAK/STAT signaling. PLoS One. 2011 Apr 14;6(4):e18552.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
甲磺酸倍他司汀片治疗耳石症复位后残余头晕的疗效研讨
DOI：10.19368/ki.2096-1782.2023.24.086甲磺酸倍他司汀片治疗耳石症复位后残余头晕的疗效研讨谢书华上海市杨浦区控江医院耳鼻喉科，上海200090[摘要]目的分析在耳石症复位后残余头晕患者中甲磺酸倍他司汀片的治疗效果。
方法选择2021年5月—2023年6月上海市杨浦区控江医院治疗的62例耳石症复位后残余头晕患者作为研究对象，按照治疗方式分为控制组和研究组，各31例。
控制组进行手法复位治疗，研究组在控制组治疗方案基础上给予患者甲磺酸倍他司汀片治疗，对比两组患者的康复指标、脑血流速度、治疗有效率。
结果治疗后，研究组患者的眩晕障碍量表评分、前庭症状指数评分低于控制组，Berg平衡量表评分高于控制组，差异有统计学意义（P均< 0.05）。
研究组患者右椎动脉、左椎动脉、基底动脉的平均血流速度均高于控制组，差异有统计学意义（P均< 0.05）。
研究组患者的总有效率（96.77%）高于控制组（77.42%），差异有统计学意义（χ2=5.166，P=0.023）。
结论在治疗耳石症复位后残余头晕的过程中，使用甲磺酸倍他司汀片价值发挥显著，临床意义深远。
[关键词]耳石症复位后残余头晕；甲磺酸倍他司汀片；疗效[中图分类号]R764 [文献标识码]A [文章编号]2096-1782（2023）12(b)-0086-04Study on the Efficacy of Betahistine Mesylate Tablets in the Treatment of Residual Dizziness after Repositioning of OtolithiasisXIE ShuhuaDepartment of Otorhinolaryngology, Shanghai Yangpu District Kongjiang Hospital, Shanghai, 200090 China[Abstract] Objective To analyze the therapeutic effect of betahistine mesylate tablets in patients with residual dizzi⁃ness after repositioning of otolithiasis. Methods A total of 62 patients with residual dizziness after repositioning of oto⁃lithiasis who were treated at Shanghai Yangpu District Kongjiang Hospital from May 2021 to June 2023 were selected as the study subjects. They were divided into a control group and a study group according to the treatment method, with 31 cases in each group. The control group was treated with manipulative repositioning, and the study group was given betahistine mesylate tablets on the basis of the treatment program of the control group. The rehabilitation indica⁃tors, cerebral blood flow rates, and treatment effectiveness of the two groups of patients were compared. Results After treatment, the vertigo disorder scale score of the study group and vestibular symptom index score were lower than those of the control group, while the Berg balance scale score was higher than that of the control group, and the differ⁃ences were statistically significant (all P<0.05). The mean blood flow velocity of right vertebral artery, left vertebral artery, and basilar artery in the study group were higher than that in the control group, and the differences were sta⁃tistically significant (all P<0.05). The total treatment effectiveness rate of patients in the study group (96.77%) was higher than that in the control group (77.42%), and the difference was statistically significant (χ2=5.166, P=0.023).Conclusion In the treatment of residual dizziness after repositioning of otolithiasis, the use of betahistine mesylate tablets has significant value and profound clinical significance.[Key words] Residual dizziness after repositioning of otolithiasis; Betahistine mesylate tablets; Therapeutic effect近几年，耳石症发病率呈上升趋势，最常见的表现是有强烈的眩晕感，一般持续1 min以内，严重[作者简介] 谢书华（1982-），女，本科，主治医师，研究方向为耳源性眩晕疾病。
COBE Spectra血细胞分离机MNC程序和Auto PBSC程序外周血造血干细胞采集效果评价
甘肃医药2020年39卷第12期Gansu Medical Journal ，2020，Vol.39，No.12外周血造血干细胞移植（peripheral blood hemato-poietic stem cell trans plantation ，PBSCT ）因其外周血干细胞采集、冻存方便，安全性高［1-2］，移植后患者免疫和造血系统功能重建较快，移植相关的死亡率低，已成为治疗恶性血液病及免疫性疾病的重要手段［3-4］。
外周血造血干细胞（peripheral blood hematopoietic stem cell ，PBSC ）的质量和数量是影响PBSCT 成功的关键因素之一。
目前，国内外对不同血细胞分离机PBSC 采集效果的报道较多，但对COBE Spectra 血细胞分离机MNC 和Auto PBSC 程序采集效果的报道并不多见。
本研究回顾了我院2017年1月~2019年12月应用COBE Spectra 血细胞分离机两种采集程序对66例患者进行149次PBHSC 采集，对采集效果、采集前后部分血常规指标的变化和采集过程中发生的不良反应进行了回顾性分析评估，现报道如下。
1材料和方法1.1一般资料选择2017年1月至2019年12月，利用COBE Spectra 血细胞分离机的MNC 和Auto PB －SC 程序采集我院血液科患者外周血自体干细胞66例（共149人次），年龄17~66岁，平均（43.5±9.19）岁，其中男性38例，女性28例，多发性骨髓瘤（Multiplemyeloma ，MM ）19例，非霍奇金淋巴瘤（non-Hodgkin lym-phoma ，NHL ）15例，霍奇金淋巴瘤（Hodgkin lymphoma ，HL ）4例，急性髓系白血病（acute myelocytic leukemia ，AML ）23例，急性淋巴细胞白血病（acute lymphoblastic leukemia ，ALL ）5例。
哈姆尔曼高压注射泵商品介绍说明书
Injection pumpsMethanolLDHIGlycolwww.process-pumps.deHammelmann offer a wide rangeof high pressure pumps for thechemical, oil and gas industries.Visit our website.Asphaltene InhibitorParaffin InhibitorCorrosion InhibitorScale Inhibitor INNOVATION THROUGH EXPERIENCEHammelmann Injection PumpsCalder offer a wide range of highpressure pump packages incorporatingHammelmann pumps for the chemical,oil and gas industries.Visit our website.www.process-pumps.deLabyrinth sealThis seal design which is absolutely unique to Hammelmann enables safe, reliable, continuous duty operation at pressures up to 3800 bar.The high pressure seal is formed within the minute cylindrical gap between the plunger and the labyrinth insert. The medium pressure is continuously reduced along the sealing surface.A minimum amount of high pressure leakage serving as lubricant is returned to the pump suction chamber.Exclusive sealing systemThe plunger connection to thepower end is self centering thereby drastically reducing sideways forces. This design ensures that there is virtually no contact between the plunger and the labyrinth insert resulting in extremely low component wear.When the pump unit is shut down the medium remains in thecylindrical gap so that a re-start,even after an extended shut down period is assured.Wear at the high pressure seal components does not lead to an abrupt breakdown of the pump but rather a gradual decrease in the flow rate. If the pump is driven in a control loop the r.p.m. of the driver will increase in direct proportion to component wear.S p e e dThe running speed of the pump is a direct indicator of the extent of wear.This enables long term planning of maintenance intervals and targeting ofspecific servicing tasks.We manufacture extremely compact Triplex and Quintuplex pump units for injection of Methanol, LDHI,Glycol and a range of inhibitors.Hammelmann high pressure pump units in the pressure range up to 15,000 psi (1035 bar) havedeveloped into the standard choice for offshore methanol injection applications with a reputation for extreme reliability and minimal maintenance requirements.Compact constructionExtensiveperformancerangeWith both Triplex andQuintuplex pumpsavailable we cansupply a veryextensive range offlow rates andoperating pressures.Power ratingsup to 1000 HPup to 750 kWFlow ratesup to 530 gpmup to 2000 l/minOperating pressuresup to 55,000 psiup to 3800 barHammelmann pumps producemaximum performance from aminimal footprint which is the resultof combining a compact integralspeed reduction gear end with theconcept of a vertical configuration.The vertical configuration channelsoscillating forces directlydownwards into the base structure.Unwanted lateral oscillations asproduced by horizontal pumps donot occur.The integral speed reducer with twinhelical gears arranged in a herringbone configuration ensures smoothrunning and even powertransmission without axially loadingthe bearings.A selection of gear ratios isavailable to allow the optimal choiceof driver. The compact constructioneliminates the need for an externalgear box and prevents rotaryoscillation. Mechanical efficiency isin excess of 95%.Industrial pumps, series 2ValvesThe suction valve (below) is a discring design incorporating a onepiece suction and discharge valveseat.FeaturesSeries 2 pumps employ the sameprecision engineered, field provencomponents as Hammelmannstandard production pumps. Theyare extremely compact with lowmaintenance costs and highoperational efficiency.Plunger speedUnitsOur high pressure pump units canbe supplied with electric motor, achoice of controls, safety valves andsuction side/discharge sidepulsation dampers.HDP 752HDP 482HDP 362HDP 252HDP172HDP 122HDP 72HDP 42HDP 2200,20,40,60,81,01,21,4Plunger speed m/sec1,61,8Moderate plunger speeds result inlow plunger and sealing elementwear characteristics.OUTINSealmonitoringsystemSeal monitoringThe condition of the low pressureseals may be monitored by installingan optional sealmonitoring system.MaintenancePump maintenance is carried outfrom above. Once the pump head isremoved you have complete,uncomplicated access to all highpressure components.Pump headThe total pressurised fluid productof the individual cylinders collectswithin a single high pressuredischarge bore within the pumphead valve block. The coaxial valvearrangement eliminates alternatingstress within the valve block.Suction chamberThe process fluid enters the pumpvia the suction chamber. Thistotally encloses the high pressurecomponents in a protective barrierand prevents emission of mediumto atmosphere.5,000 psi345 bar 10,000 psi 690 bar 15,000 psi 1035 bar Crankspeed HDP 22 D 20 D 15 D 12750 rpm 5 gpm 19l/min 2.6 gpm 10 l/min 1.6 gpm 6 l/min HDP 42 D 35 D 26 D 20750 rpm 15 gpm 60 l/min 8 gpm 31 l/min 4.7 gpm18 l/min HDP 72D 35 D 26 D 22750 rpm 21 gpm 80 l/min 11 gpm 42 l/min 7.4 gpm 28 l/min HDP 122 D 55 D 35 D 30530 rpm 50 gpm 192 l/min 19 gpm 74 l/min 13 gpm 51 l/min HDP 172 D 50 D 35 D 30555 rpm 61 gpm 232 l/min 28 gpm 108 l/min 20 gpm 75 l/min HDP 252 D 50 D 35 D 30555 rpm 102 gpm 387 l/min 47 gpm 181 l/min 32 gpm 124 l/min HDP 362 D 80 D 60 D 45490 pm 138 gpm 525 l/min 74 gpm 282 l/min 38 gpm 146 l/min HDP 482 D 80D 60 D 45465 rpm 171 gpm650 l/min92 gpm 349 l/min 47 gpm 181 l/min HDP 752D 80D 60D 45465 rpm285 gpm 1080 l/min159 gpm603 l/min79 gpm302 l/minPerformance data, Industrial pumps, series 2(Selection)Pos.Part name Pos.Part name 1Discharge valve 8Low pressure seal pack 2Valve housing 9Bellow 3Suction valve 10Crosshead4Suction chamber 11Connection rod 5Sleeve 12GearHDP 22/42: belt drive 6Labyrinth insert 13Crank shaft7Plunger14Crank section housing1234567891011121314Recommendations and standardsEU Machine directive 98/37/ EU ATEX 94/9/EUAPI 674 (with exceptions)Technical data, Industrial pumps, series 2Standard Option PlungerLabyrinth insert Ceramic Bronze-Valve housing 17% Chromium steel22% Duplex steelSealsNBR / PolyamideFKM / PEEK Suction chamberBronze18 – 10Chromium Nickel steel* Right reserved to make technical modificationsWetted parts materials *Gas tight designThe intermediate chamber of the pump can be outfitted with gas tight covers which provide a seal to atmosphere. The chamber is then charged with inert gas.This design ensures that no fluids, vapours or gases can escape to atmosphere via a worn plunger seal.1 = Priming valve2 =Safety valve3=Pressure regulating valveBellows systemThe bellows are the hermetic seals for the power end to prevent the intrusion of fluid or gas. They are available in FKM, H-NBR and PTFE.Process pumps, series 5ValvesTo ensure that the pumpconstructíon is appropiate for the pumped medium we have a number of alternative valve designsavailable. In the example shown below the suction and discharge valves are conical. The suction and discharge valve seats are combined in one component.FeaturesSeries 5 pumps are built to the highest standards of safety and reliability. We can supplycomponents from a wide range of materials to suit the pumped medium.Our latest variation of this pump series is the Zero emission where the pumped fluid is hermetically sealed within the pump, preventing leakage to atmosphere during operation.Plunger speedUnitsYour complete pump unit can be outfitted with suction and/or discharge pulsation dampersdimensioned, manufactured, tested and certified to your specification.1,4HDP 755HDP 485HDP 365HDP 255HDP 175HDP 125HDP 75HDP 45HDP 2500,20,40,60,81,01,2Plunger speed m/secInert gasOUTINThe series 5 pumps areconservatively rated for power with low plunger speeds ensuring limited wear of plungers and sealing elements.32Seal monitoring 11Performance data, Process pumps, series 5 (Selection)5,000 psi345 bar 10,000 psi 690 bar 15,000 psi 1035 bar Crank speed HDP 25 D 20 D 15 D 12420 rpm 2.9 gpm 11 l/min 1.5 gpm 6 l/min 0.9 gpm 3,5 l/min HDP 45 D 35 D 26 D 20500 rpm 10 gpm 40 l/min 5 gpm 20 l/min 3 gpm 12 l/min HDP 75 D 35 D 26 D 22490 rpm 13 gpm 52 l/min 7 gpm 28 l/min 5 gpm 19 l/min HDP 125 D 55 D 35 D 30365 rpm 35 gpm 133 l/min 13 gpm 51 l/min 9 gpm 35 l/min HDP 175 D 50 D 35 D 30385 rpm 42 gpm 160 l/min 19 gpm 74 l/min 13 gpm 52 l/min HDP 255 D 50 D 35 D 30390 rpm 71 gpm 270 l/min 33 gpm 126 l/min 23 gpm 87 l/min HDP 365 D 80 D 60 D 45340 rpm 95 gpm 363 l/min 51 gpm 194 l/min 26 gpm 101 l/min HDP 485 D 80 D 60 D 45365 rpm 137 gpm 520 l/min 73 gpm 279 l/min 38 gpm 145 l/min HDP 755D 80D 60D 45365 pm229 gpm867 l/min127 gpm483 l/min63 gpm242 l/minD = Piston dia [mm]1234567891011121314Technical data, Process pumps, series 5Wetted parts materials *Recommendations and standardsEU Machine directive 98/37/ EUATEX 94/9/EUAPI 674 (with exceptions)Other customer specified standards, i.e.NORSK M501NORSOK M650NACE MR 0175Pos.Part name Pos.Part name 1Discharge valve 8Low pressure seal pack 2Valve housing 9Bellows 3Suction valve 10Crosshead4Suction chamber 11Connection rod 5Sleeve 12GearHDP 25/45: belt drive 6Labyrinth insert 13Crank shaft7Plunger14Crank section housingStandardOptionPlungerLabyrinth insert Ceramic BronzeTungsten carbide Tungsten carbide Valve housing 22% Duplex steel25% Super duplex steel SealsNBR / PolyamideFFKM / PEEKSuction chamber 18–10 Chromium Nickel steel 25% Superduplex steel * Right reserved to make technical modificationsRound the clock operationThe compact design ofHammelmann pumps is a space saving advantage for installation on offshore platforms and FPSO’s.They are increasingly specified as the pumps of choice for offshore installations.02/09© Copyright Hammelmann Maschinenfabrik GmbH, Oelde, Germany. Right reserved to make technical modificationsAgbami Aker 1-6Allegheny Anna Platform Atlantis Auger Auger Apit Baton Rouge Black Widow BrazilBrutus/Glider BS4Cabida Block Canyon Express Conger Salsa Demos ForvieGarden Banks Garnet Gjoa Semi Groupo R Hickory HolsteinHorn Mountain HoumaIndep. Hub 3IndpendenceK2 Green Canyon K-FelsKikeh-Gusto King Kong Kings PeekKristin Longhorn Mad Dog Magnolia Marco Polo Max-Stena-Drill Mobile Rig Morvin Asgard Neptune Nile NoonanNorse Marchand Panama City Pegasus Perdido Petrorig Producer Scarebo Schahin SevanS. Timbalier Statfjord B & C Tahiti Talisman Tanzanite Tarantula TMT 1TyphonUrsa-Princess Valifornia West EdrillHDP 72 unit for methanol duty Op. pressure 12,000 psi – 830 bar Flow rate 6 gpm – 24 l/minHDP 555 pump unit for glycol and methanol dutyOp.pressure 10,700 psi – 740 bar, Flow rate 87 gpm – 333 l/minHDP 115 units for methanol duty Op. pressure 15,000 psi – 1035 bar Flow rate 1.5 gpm – 6 l/minHDP 122 unit for LDHI dutyOp. pressure 15,000 psi – 1035 bar Flow rate 7 gpm – 28 l/minHDP 175 units for methanol duty Op. pressure 5,300 psi – 370 bar Flow rate 46 gpm – 176 l/minHammelmannMaschinenfabrik GmbH Zum Sundern 13-2159302 Oelde – Germany Tel. +45 2522 760Fax +49 2522 76444******************www.hammelmann.deCalder Ltd.Gregory's Bank Worcester WR3 8ABUnited Kingdom Phone: 0044 1905 723 255Fax: 0044 1905 723 904***************.uk Calder Ltd.Gregory’s Bank Worcester WR3 8AB United KingdomPhone: 0044 1905 723 255Fax: 0044 1905 723 904***************.uk The compact design of Calder pump packages incorporatingHammelmann pumps, offers a space saving advantage for installation on offshore platforms and FPSO’s. They are increasingly specified as the pumps of choice for offshore installations.。
血清C_肽与糖化血红蛋白联合检验在糖尿病临床诊断中的效果分析
· 医学检验 ·糖尿病新世界 2023年4月糖尿病新世界 DIABETES NEW WORLD血清C 肽与糖化血红蛋白联合检验在糖尿病临床诊断中的效果分析郑梅淋，田萍萍，钟秋蓉厦门市海沧医院检验科，福建厦门 361000[摘要] 目的 分析糖尿病临床诊断中应用血清C 肽联合糖化血红蛋白检验的效果。
方法 选取厦门市海沧医院2020年1月—2021年12月收治的200例疑似糖尿病患者为研究对象，将口服葡萄糖耐量试验作为诊断金标准，分别对患者施以血清C 肽检验和糖化血红蛋白检验，比较两组的血清C 肽、血清C 肽联合糖化血红蛋白检验结果。
结果 在200例疑似糖尿病患者中，糖耐量试验检查确诊患者180例，占比90.00%，血清C 肽检测下，阳性检出率为98.33%（177例），血清C 肽联合糖化血红蛋白检测下，阳性检出率为86.11%（155例）。
联合检测的灵敏度、特异度、准确率优于单一检测，差异有统计学意义（P <0.05）。
结论 血清C 肽联合糖化血红蛋白检验能够提升糖尿病临床诊断准确性，可为临床诊断提供更为科学的参考依据。
[关键词] 血清C 肽；糖化血红蛋白；糖尿病；诊断；准确度；联合检验[中图分类号] R59 [文献标识码] A [文章编号] 1672-4062（2023）04（b ）-0066-04Effect Analysis of Combined Test of Serum C-peptide and GlycosylatedHemoglobin in Clinical Diagnosis of Diabetes MellitusZHENG Meilin, TIAN Pingping, ZHONG QiurongDepartment of Laboratory Medicine, Xiamen Haicang Hospital, Xiamen, Fujian Province, 361000 China[Abstract ] Objective To analyze the effect of serum C-peptide combined with glycosylated hemoglobin test in the clinical diagnosis of diabetes. Methods We selected 200 patients with suspected diabetes who were admitted to Xia‐men Haicang Hospital from January 2020 to December 2021 as the research object, and took the oral glucose toler‐ance test as the diagnostic gold standard. Serum C-peptide test and Glycated hemoglobin test were performed on thepatients, and the results of serum C-peptide, serum C-peptide and Glycated hemoglobin test were compared betweenthe two groups. Results Among 200 suspected diabetes patients, 180 patients were diagnosed by Glucose tolerancetest, accounting for 90.00%. The positive detection rate was 98.33% (177 cases) by serum C-peptide test, and 86.11% (155 cases) by serum C-peptide combined with Glycated hemoglobin test. The sensitivity, specificity, and accuracy of combined detection were better than those of single detection, and the difference was statistically significant (P <0.05).Conclusion Serum C-peptide combined with Glycated hemoglobin test can improve the accuracy of clinical diagnosis of diabetes and provide more scientific reference for clinical diagnosis.[Key words ] Serum C-peptide; Glycosylated hemoglobin; Diabetes; Diagnosis; Accuracy; Combined test糖尿病是常见的慢性代谢性疾病，主要因为胰岛素代谢紊乱而引起的代谢性疾病，按照疾病成因，可分成1型糖尿病和2型糖尿病两种类型。
华蟾素联合紫杉醇对骨肉瘤U_(2)OS细胞抑制作用的研究
甘肃医药2021年40卷第6期Gansu Medical Journal ，2021，Vol.40，No.6华蟾素联合紫杉醇对骨肉瘤U 2OS 细胞抑制作用的研究马秀才1李晶2马晓燕1罗国栋1王建澍2绽春蕊1俞永智1宋建民11.甘肃省人民医院，甘肃兰州730000；2.甘肃省肿瘤医院，甘肃兰州730050【摘要】目的：探讨华蟾素联合紫杉醇对人骨肉瘤细胞增殖的抑制作用及机理。
方法：体外培养人骨肉瘤U 2OS 细胞，按照实验设计分为对照组、华蟾素组、紫杉醇组、华蟾素联合化疗药组，每组在不同实验条件下按不同时间点（24，48，72h ）进行检测。
MTT 法检测各组骨肉瘤细胞生长的抑制率，TUNEL 染色观察细胞凋亡程度并计算其凋亡率，免疫荧光染色检测凋亡相关蛋白Bax 和Bcl-2的含量并计算其比值，RT-PCR 、Western Blot 法检测凋亡相关及Wnt/β-catenin 通路相关蛋白的表达。
结果：MTT 结果显示，华蟾素联合化疗药组细胞生存率明显降低，该组细胞被药物作用48h 后生存率是（24.58±1.65）%，相当于紫杉醇组同期（40.85±1.34）%的1/2（P <0.01）。
TUNEL 染色显示，与作用于细胞24，48h 相比，作用72h 后凋亡率达到（60.35±1.57）%，凋亡率明显增加（P <0.01）。
免疫荧光、RT-PCR 及Western Blot 法结果提示，随着药物作用时间的延长，华蟾素联合化疗药组Bax 的表达逐渐增加，而Bcl-2的表达逐渐减少，Bax/Bcl-2含量的比值也逐渐增加。
同时，Wnt/β-catenin 通路关键蛋白β-catenin 、caspase-3的表达也逐渐增加。
结论：华蟾素具有抑制骨肉瘤U 2OS 细胞增殖和诱导其凋亡的作用，其联合化疗药在疗效上呈时间依赖性，而其机制可能与激活Wnt/β-catenin 通路相关。
糖尿病患者诊断应用血清C肽及糖化血红蛋白联合检测的价值分析
DOI：10.16658/ki.1672-4062.2023.14.085糖尿病患者诊断应用血清C肽及糖化血红蛋白联合检测的价值分析倪胜南，陈少，陈一鸣泗阳康达医院检验科，江苏宿迁223700[摘要]目的探讨糖尿病患者诊断应用血清C肽联合糖化血红蛋白检测的价值。
方法将2022年1月—2023年1月泗阳康达医院收治的74例疑似糖尿病患者作为研究对象，检测入组患者糖化血红蛋白（glycosylated hemoglobin, HbA1c）以及血清C肽水平，以口服葡萄糖耐量试验（glucose tolerance test check, OGTT）为金标准，统计血清C肽联合糖化血红蛋白检测与单一项目检测的敏感性、特异度和诊断符合率。
结果74例疑似糖尿病患者根据葡萄糖耐量试验结果，确诊患者67例，确诊率为90.54%（67/74）；与血清C肽、HbA1c单一检测相比，血清C肽+HbA1c联合检测敏感度更高，差异有统计学意义（P<0.05）；血清C肽+HbA1c联合检测的特异度略高于血清C肽、HbA1c单一检测，但差异无统计学意义（P>0.05）；联合检测诊断符合率明显高于血清C 肽、HbA1c单项检测，差异有统计学意义（P<0.05）。
结论血清C肽与糖化血红蛋白是临床诊断糖尿病的重要参考指标，二者表达水平的变化有助于检测患者胰岛素分泌功能，评估疾病严重程度，两者联合检验灵敏性与特异度良好，有助于早期明确诊断，临床参考价值较高。
[关键词] 糖尿病；血清C肽；糖化血红蛋白；诊断价值[中图分类号] R446.1 [文献标识码] A [文章编号] 1672-4062（2023）07（b）-0085-04Analysis of the Value of the Diagnostic Application of Combined Serum C-peptide and Glycosylated Hemoglobin Testing in Patients with Diabetes MellitusNI Shengnan, CHEN Shao, CHEN YimingDepartment of Laboratory Medicine, Siyang Kangda Hospital, Suqian, Jiangsu Province, 223700 China[Abstract] Objective To explore the value of applying serum C-peptide combined with glycated hemoglobin test for the diagnosis of diabetic patients. Methods A total of 74 patients with suspected diabetes admitted to Siyang Kangda Hospital from January 2022 to January 2023 were selected as the research objects. The levels of glycosylated hemoglo‐bin (HbA1c) and serum C-peptide were detected. Oral glucose tolerance test (OGTT) was used as the gold standard. The sensitivity, specificity and diagnostic coincidence rate of serum C-peptide combined with glycosylated hemoglo‐bin detection and single item detection were statistically analyzed. Results According to the results of glucose toler‐ance test, 67 patients were diagnosed in 74 patients with suspected diabetes, and the diagnosis rate was 90.54% (67/ 74). Compared with the single detection of serum C-peptide and HbA1c, the sensitivity of combined detection of se‐rum C peptide and HbA1c was higher, and the difference was statistically significant (P<0.05). The specificity of com‐bined detection of serum C-peptide and HbA1c was slightly higher than that of single detection of serum C-peptide and HbA1c, but the difference was no statistically significant (P>0.05). The diagnostic coincidence rate of combined detection was significantly higher than that of single detection of serum C-peptide and HbA1c, and the difference was statistically significant (P<0.05). Conclusion Serum C-peptide and glycosylated hemoglobin are important reference indexes for clinical diagnosis of diabetes mellitus, and changes in the expression levels of the two can help to detect the insulin secretion function of patients and assess the severity of the disease. The sensitivity and specificity of the [作者简介]倪胜南（1991-），女，本科，主管检验师，研究方向为免疫学、分子生物学检验。
抗体公司
赛信通（上海）生物试剂有限公司
上海市浦东南路1101号远东大厦514室，200120 info@cst www.cst 2158356288 公司总部: 美国
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privatelyowned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activationstate and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine. 总引用数为4670，来自于1966篇文章。最常引用的试剂包括： Akt, ERK2, ERK1, p38, Akt1。
AbD Serotec (BioRad)
肝病专业英语词汇
3α-羟类固醇脱氢酶(Y' 蛋白) γ -谷氨酰转移酶 γ-氨基丁酸 甲胎蛋白 人兽共患病 异种肝移植 脂肪性纤维瘤,黄色瘤 黄嘌呤氧化酶 黄斑瘤 全球移植中心名录 窗口期 肝豆状核变性 肥达反应 外斐反应 韦克斯勒成人智力测验 呕吐 视觉诱发电位 病毒学应答 病毒复制 病毒性肝炎 静脉-静脉转流 VOD 肝小静脉闭塞病 静脉-动脉转流 血管活性肽 静脉曲张 胆管消失综合征 疫苗 熊去氧胆酸 尿胆素原 尿胆素 二磷酸尿苷异构酶 尿素生成 鸟氨酸循环,尿素循环 上消化道出血 粗纤维调节素 肝未分化肉瘤 充盈不足学说 非结合高胆红素血症 游离胆红素,非结合胆红素 超声(波)检查法
短潜伏期肝炎 移动性浊音 腹水白蛋白浓度梯度 血清肝炎 血清诊断 血清胆红素 血清白蛋白 血清学应答 乙肝血清学检查 血清转换 败血症相关胆汁淤积 正链,有义链 镇静剂 次级胆酸 海蓝组织细胞增多症 硬化疗法 硬化性胆管炎 日本血吸虫病 湄公血吸虫 曼氏血吸虫 日本血吸虫 间插血吸虫 埃及血吸虫 血吸虫 瘢痕形成期 粗面内质网 滚环机制(环状DNA复制的机理) RNA干扰 核酶 核糖体 胆固醇逆向转运
伤寒 Ⅳ型胶原 Ⅲ型前胶原 甲肝和乙肝疫苗 抑癌基因 肿瘤坏死因子 肝结核 滋养体 甘油三酯 颠换效应 经颈静脉肝内门腔分流 转换 输血传染的病毒 输血性肝炎 转化生长因子
transcatheter arterial chemoembolization 肝动脉化疗栓塞 trans-activation toxic hepatitis total cholesterin total bilirubin tomor necrosis factor tocopherol TNF-related apoptosis inducing ligand tissue inhibitor of metalloproteinase thymosin Thymopolypeptides for Injection thromboxane the core promoter element tentative diagnosis tension of muscle tenderness Telbivudine taurocholic acid taurochenodeoxycholate acid systemic inflammatory response syndrome syncytial giant-cell hepatitis sustained virus response sustained response 反式激活 中毒性肝炎 总胆固醇 总胆红素 肿瘤坏死因子 生育酚,维生素E 肿瘤坏死因子相关凋亡诱导配体 基质金属蛋白酶组织抑制物 胸腺肽 胸腺肽 血栓素 核心启动子元件,启动子核心元件 暂时的(假定的)诊断,试验性诊断 肌张力 压痛 LdT 牛(磺)胆酸 牛磺鹅(去氧)胆酸盐,牛磺鹅(脱氧)胆酸盐 全身炎症反应综合症 融合巨细胞性肝炎 持续病毒应答 持久应答
中医治疗肥胖型2_型糖尿病的进展分析
中医治疗肥胖型2型糖尿病的进展分析马香菊1，刘飞21.邹城市中医院肿瘤科，山东邹城273500；2.邹城市中医院内一科，山东邹城273500[摘要]肥胖型2型糖尿病（Type 2 Diabetes Mellitus, T2DM）作为全球范围内流行的慢性代谢性疾病，其治疗一直备受关注。
近年来，中医治疗在改善T2DM患者的胰岛功能、降低血糖水平、改善血脂代谢等方面取得了一些积极的成果。
中医治疗通常注重整体调理，强调平衡阴阳、调理气血。
本文综述了中医治疗肥胖型T2DM的最新研究成果，涵盖了治疗方法、机制、临床疗效等方面的重要进展。
旨在为医学界提供参考，促进相关领域的深入研究和治疗方法的不断优化。
[关键词] 中医；肥胖型；糖尿病；综述[中图分类号] R4 [文献标识码] A [文章编号] 1672-4062（2024）02（a）-0194-05 Progress Analysis of Traditional Chinese Medicine Treatment of Obese Type 2 Diabetes MellitusMA Xiangju1, LIU Fei21.Oncology Department, Zoucheng Traditional Chinese Medicine Hospital, Zoucheng, Shandong Province, 273500 China;2.Internal Department Section One, Zoucheng Traditional Chinese Medicine Hospital, Zoucheng, Shandong Province, 273500 China[Abstract] As a chronic metabolic disease prevalent worldwide, the treatment of obese type 2 diabetes mellitus (T2DM) has attracted much attention. In recent years, traditional Chinese medicine treatment has achieved some posi⁃tive results in improving islet function, lowering blood sugar level and improving lipid metabolism in patients with T2DM. Traditional Chinese medicine treatment usually focuses on overall conditioning, emphasizing balance of Yin and Yang, conditioning of qi and blood. This article reviews the latest research results of traditional Chinese medicine treatment of obese T2DM, including important advances in treatment methods, mechanisms and clinical effects. It aims to provide reference for the medical community and promote in-depth research in related fields and continuous optimization of treatment methods.[Key words] Traditional Chinese medicine; Obese type; Diabetes mellitus; Summarize肥胖型2型糖尿病（Type 2 Diabetes Mellitus, T2DM）是一种以胰岛素抵抗和胰岛功能不足为特征的慢性代谢性疾病，其特征还包括胰岛功能不足、高血糖、肥胖和高血压等[1-2]。
重组贻贝粘蛋白的表征及功效评价
生物技术进展 2023 年 第 13 卷 第 4 期 596 ~ 603Current Biotechnology ISSN 2095‑2341研究论文Articles重组贻贝粘蛋白的表征及功效评价李敏 ， 魏文培 ， 乔莎 ， 郝东 ， 周浩 ， 赵硕文 ， 张立峰 ， 侯增淼 *西安德诺海思医疗科技有限公司，西安 710000摘要：为了推进重组贻贝粘蛋白在医疗、化妆品领域的应用，对大肠杆菌规模化发酵及纯化生产获得的重组贻贝粘蛋白进行了表征及功效评价。
经Edman 降解法、基质辅助激光解吸电离飞行时间质谱、PITC 法、非还原型SDS -聚丙烯酰胺凝胶电泳法、凝胶法、改良的Arnow 法对重组贻贝粘蛋白进行氨基酸N 端测序、相对分子量分析、氨基酸组成分析、蛋白纯度分析、内毒素含量测定、多巴含量测定；通过细胞迁移、斑马鱼尾鳍修复效果对重组贻贝粘蛋白进行功效评价。
结果显示，获得的重组贻贝粘蛋白与理论的一级结构一致，蛋白纯度达95%以上，内毒素<10 EU ·mg -1,多巴含量大于5%；重组贻贝粘蛋白浓度为60 μg ·mL -1时能够显著促进细胞增殖的活性（P <0.01）；斑马鱼尾鳍面积样品组与模型对照组相比极显著增加（P <0.001）。
研究结果表明，重组贻贝粘蛋白具有显著的促细胞迁移和修复愈合的功效，具备作为生物医学材料的潜质。
关键词：贻贝粘蛋白；基因重组；生物材料；表征；功效评价DOI ：10.19586/j.20952341.2023.0021 中图分类号：S985.3+1 文献标志码：ACharacterization and Efficacy Evaluation of Recombinant Mussel Adhesive ProteinLI Min ， WEI Wenpei ， QIAO Sha ， HAO Dong ， ZHOU Hao ， ZHAO Shuowen ， ZHANG Lifeng ，HOU Zengmiao *Xi'an DeNovo Hith Medical Technology Co.， Ltd ， Xi'an 710000， ChinaAbstract ：In order to promote the application of recombinant mussel adhesive protein in the medical and cosmetics field ， the recombi⁃nant mussel adhesive protein obtained from scale fermentation and purification of Escherichia coli was characterized and its efficacy was evaluated. Amino acid N -terminal sequencing ， relative molecular weight analysis ， amino acid composition analysis ， protein purityanalysis ， endotoxin content ， dihydroxyphenylalanine （DOPA ） content of recombinant mussel adhesive protein were determined by the following methods ： Edman degradation ， matrix -assisted laser desorption ionization time -of -flight mass spectrometry （MALDI -TOF -MS ）， phenyl -isothiocyanate （PITC ）， nonreductive SDS -polyacrylamide gel electrophoresis （SDS -PAGE ）， gel method ， modified Ar⁃now. The efficacy of recombinant mussel adhesive protein was evaluated by cell migration and repairing effect of zebrafish tail fin. Re⁃sults showed that the obtained recombinant mussel adhesive protein was confirmed to be consistent with the theoretical primary structure ， protein purity of more than 95%， endotoxin <10 EU ·mg -1， DOPA content above 5%. When the recombinant mussel adhesive protein concentration was 60 μg ·mL -1， the effect of promoting cell proliferation was the most obvious ， and it had very significant activity （P <0.01）. The caudal fin area of zebrafish in sample group was significantly increased compared with model control group （P <0.001）. The results indicated that recombinant mussel adhesive protein can promote cell migration and repair healing and has the potential to be used as biomedical materials.Key words ：mussel adhesive protein ； gene recombination ； biological materials ； representation ； efficacy evaluation贻贝粘蛋白（mussel adhesive protein ， MAP ）也称作贻贝足丝蛋白（mussel foot protein ，Mfps ），收稿日期：2023⁃02⁃24； 接受日期：2023⁃03⁃31联系方式：李敏 E -mail:*******************;*通信作者 侯增淼 E -mail:***********************.cn李敏，等：重组贻贝粘蛋白的表征及功效评价是海洋贝类——紫贻贝（Mytilus galloprovincalis）、厚壳贻贝（Mytilus coruscus）、翡翠贻贝（Perna viri⁃dis）等分泌的一种特殊的蛋白质，贻贝中含有多种贻贝粘蛋白，包括贻贝粘蛋白（Mfp 1～6）、前胶原蛋白（precollagens）和基质蛋白（matrix proteins）等［1］。
地特胰岛素联合门冬胰岛素治疗妊娠期糖尿病疗效与安全性及对母婴结局的影响研究
DOI：10.16658/ki.1672-4062.2023.18.113地特胰岛素联合门冬胰岛素治疗妊娠期糖尿病疗效与安全性及对母婴结局的影响研究王霞平遥县人民医院产科，山西晋中031100[摘要]目的探讨妊娠期糖尿病（gestational diabetes mellitus, GDM）产妇应用地特胰岛素联合门冬胰岛素治疗的效果。
方法选取2021年7月—2022年9月期间在平遥县人民医院进行分娩的GDM产妇66例为研究对象，按隐匿数字随机法分为单药组（33例，门冬胰岛素治疗），联合组（33例，门冬胰岛素+地特胰岛素治疗），观察记录两组血糖变化、胰岛素水平、母婴结局，进行比较分析。
结果治疗前，两组患者血糖控制水平比较，差异无统计学意义（P>0.05）；治疗后，联合组的空腹血糖（fasting plasma glucose, FPG）、餐后2 h血糖（2-hourpostprandial blood glucose，2 hPG）、糖化血红蛋白（glycated hemoglobin, HbA1c）水平均低于单药组，差异有统计学意义（P<0.05）；联合组的FPG达标、2 hFPG达标、FPG和2 hFPG均达标的时间均显著短于单药组，差异有统计学意义（P<0.05）；联合组的自然分娩率为72.73%显著高于单药组的48.48%，差异有统计学意义（P< 0.05）；单药组的不良妊娠结局发生率（24.24%）高于联合组（9.09%），差异无统计学意义（P>0.05）。
结论地特胰岛素联合门冬胰岛素治疗GDM患者，可以获得较为理想的血糖控制效果，能更快的使患者血糖达到理想的标准，自然分娩率更高。
[关键词] 妊娠期糖尿病；地特胰岛素；门冬胰岛素；母婴结局[中图分类号] R714 [文献标识码] A [文章编号] 1672-4062（2023）09（b）-0113-04Study on the Efficacy and Safety of Insulin Detemir Combined with Insu⁃lin Aspart in the Treatment of Gestational Diabetes and Its Impact on Ma⁃ternal and Fetal OutcomesWANG XiaDepartment of Obstetrics, Pingyao County People's Hospital, Jinzhong, Shanxi Province, 031100 China[Abstract] Objective To explore the effect of insulin detemir combined with insulin aspart in the treatment of gesta‐tional diabetes mellitus (GDM). Methods 66 GDM women who gave birth in Pingyao County People's Hospital from July 2021 to September 2022 were selected as research objects. According to the concealed number random method, 33 patients were divided into a single-drug group (treated with insulin aspart) and 33 patients were combination group (treated with insulin aspart+insulin detemir). Observed and recorded the data on blood sugar changes, insulin levels, and maternal and infant outcomes between the two groups for comparative analysis. Results Before treatment, there was no statistically significant difference in blood glucose control levels between the two groups (P>0.05). After treat‐ment, the levels of fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2 hPG), and glycated hemoglobin (HbA1c) in the combination group were lower than those in the single-drug group, the difference was statistically sig‐nificant (P<0.05). The time for FPG to reach the target, 2 hPG to reach the target, and both FPG and 2 hPG to reach the target in the combination group were significantly shorter than those in the single-drug group, the difference were statistically significant (P<0.05). The natural delivery rate in the combination group was 72.73%, which was signifi‐cantly higher than the 48.48% in the single-drug group, the difference was statistically significant (P<0.05). The inci‐dence rate of adverse pregnancy outcomes in the single-drug group (24.24%) was higher than that in the combination group (9.09%), and the difference was statistically significant (P>0.05). Conclusion Insulin detemir combined with in‐sulin aspart can achieve ideal blood sugar control effects in patients with GDM, and can bring patients' blood sugar to the ideal standard faster, and the natural delivery rate is higher.[作者简介]王霞（1979-），女，本科，副主任医师，研究方向为产科及相关疾病诊治。
Expression, Purification and Crystallization of
Expression, Purification and Crystallization of the Mycobacterium Tuberculosis HSP16.3 Molecular Chaperone Background of Mycobacterium Tuberculosis HSP16.3HSP16.3, a 16.3 kDa protein from Mycobacterium Tuberculosis, was originally identified as a prominent antigen (Kingston et al., 1987). During the stationary phase, HSP16.3 is maximally expressed and becomes a main protein of the latent phase (Yuan et al., 1996). Previous studies showed that HSP16.3 can make the cell structure stable and prevent stationary Mycobacterium Tuberculosis from autolysing (Cunningham et al., 1998). In previous studies, HSP16.3 was found as one of theα-crystallin-related small heat shock proteins (sHSP) with molecular chaperone activity. Experiments in vitro revealed that HSP16.3 can suppress the thermal aggregation of citrate synthase at 39.5˚C, without consumption of A TP (Chang et al., 1996).Now the Mycobacterium Tuberculosis HSP16.3 gene was cloned to the plasmid pSTE-HSP16.3, and transformed to E.Coli. BL21(DE3) strain.Material and MethodExpressionThings to have ready before Starting.-Plate or glycerol culture-Sterile LB 25ml in a 50mL shaker flasker, 250ml in a 500mL shaker flasker, all together autoclaved, antibiotic added afterword.- antibiotic and sterile water- TipsPrepare the LB and autoclave:Fomula of the LB medium for 1 Liter:Bacto Tryptone (BT) 10 gBacto Y east Extract (BYE) 10 gNaCl 10gThe LB medium, dd H2O and the tips all together autoclaved at 121 ˚C for 20 minutes.Method:1 Innoculate 25 ml LB Medium ( containing 100 ug) and grow culture overnight(37˚C, 200rpm).2 Next morning inoculate 250 ml prewarmed LB Medium ( containing 100 ug) with the 25 ml overnight culture and grow at 37 ˚C, 200rpm, HSP16.3 was overexpressed in soluble form intracellularly without IPTG induction.3 Incubate the Culture for 10 hours before havesting the cell at 4000 g for 20 minutes.4 Resuspend the cell pellet in 30 ml Butter A and freeze the Sample in -80˚C refigerator.PurificationDE52 Ion-Exchange columnThings to have ready before Starting.-Butter A: 50 mM Imidazole pH 6.5 (1 liter)-Butter B: 50 mM Imidazole pH 6.5 , 300mM NaClall together Fitrate with 0.2 um membrane.- DE52 medium , column ,Gradient maker, UV-monitor and Fractioner- TipsMethod:1 Thaw the cell pellet and vortex .2 Add 0.4ml 100 mM PMSF and sonicate (400kw, 4s-6s 50 cycle* 5 )3 Centrifuge 15000 rpm, 30 minutes to pellet debris4 Transfer supernatant to a 50 ml conicale tube and discard the pellet.5 The supernatant dilute to 50 ml with Buffer A and then load to DE52 ion-exchange columns (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.6 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.7 Run 15% SDS-PAGE to determine the HSP16.3 peak.Desalting by dialysis1 Preparation of the dialysis tubeCut the tube in a suitable length (20-30 cm)Boil the tube in solution containing 10 mM NaHCO3 for a few minutes.Boil the tube in solution containing 10 mM EDTA for a few minutes.Rasin the tube with de-ion water2 Pool the HSP16.3 peak and dialysis the Sample against 1000ml Buffer A for more than 6hours.Q-Separose (HP) Ion-Exchange Column1 load the sample to Q-Separose (HP) Ion-Exchange column (20ml), which was pre-equibrated with 100ml Buffer A. And then wash the unbound proteins with 100 ml Buffer A.2 Elute the protein with a linear gradient : 200ml buffer A plus 200ml buffer B, 2ml/min, 6ml each fraction.3 Run 15% SDS-PAGE to determine the purity of the HSP16.3 peak.Gel filtration ColumnThe HSP peak was a final volumn 0.3ml and then run though a Superdex75 (HR, 10/30mm) gel filtration column in 150mM NaCl and 5mM Imdazole, pH6.5. Crystallization1 The purified HSP16.3 was solvent-exchanged to water and concentrated to 20mg/ml before crystallization trails (Bradford). All the crystallization trials were carried out using the hanging-drop vapor-diffusion method at 291K: drops consisted of2 microlitres of HSP16.3 protein solution plus 2 microlitres of the precipitant. The drops were equilibrated against 0.2 ml precipitant at room temperature. The crystallization conditions were investigated with a PEG4000 Kit.Result and discussionThe purity of the final HSP16.3 was over 95% by SDS-PAGE. The crystallization trials of HSP16.3 yielded Cubic crystals with a size of 0.8*0.8*0.6mm in a few days.20040060080010001200mAUBuffer Tris-HCL pH 8.5 Precipitant PEG 4000 MethodV apor Diffusion Temperature 293 K Size0.8*0.8*0.6mmReferencesChang Z., Primm, T.P., Jakana J., Lee H. I., Serysheva I., Chiu W., Gilber H. F., Quiocho F. A., (1996) J Biol Chem 271:7218-7223Cunningham A. F., Spreadbury C. L., (1998) J. Bacteriol. 184:801-808Kingston A. E., Salgame P. R., Mitchison N.A., Colston M. J. (1987) Infect. Immun 55,3149-3154Yuan Y., Crane D. D., Barry C. E. III (1996) J Bacteriol178: 4484-4492。
倍他米松磷酸钠注射液治疗早产有效性和安全性研究进展
2024年4月第14卷第8期·综 述·[基金项目] 郑州大学药学院国药科技创新创业基金项目（2022yxy018）。
倍他米松磷酸钠注射液治疗早产有效性和安全性研究进展王青宇1 李丝雨1 刘林凤1 刘 倩1 钟 晴1 周红建2 李俊霞21.郑州大学药学院，河南郑州 450001；2.遂成药业股份有限公司，河南新郑 451150[摘要]倍他米松是地塞米松的同分异构体，具有抗炎、抗过敏、抗内毒素和免疫抑制等功能。
倍他米松磷酸钠（BSP）注射液是倍他米松的磷酸盐制剂，作为一种糖皮质激素（ACS）类药物，其临床应用较广。
BSP 治疗早产已有充分的证据并被纳入各国指南，然而这些证据主要集中在高收入国家，中低收入国家相关证据则较少。
我国关于BSP 在产科应用疗效和安全性临床研究方面存在不足。
关于倍他米松和地塞米松疗效和安全性直接比较的临床研究较少，BSP 治疗早产后儿童期和成年期随访研究尚不足。
因此，需进一步开展相关研究，为早产临床科学合理用药提供决策依据。
[关键词]倍他米松磷酸钠注射液；早产；呼吸窘迫综合征；败血病；脑室内出血[中图分类号] R714.21 [文献标识码] A [文章编号] 2095-0616（2024）08-0058-05DOI:10.20116/j.issn2095-0616.2024.08.14Research progress on the efficacy and safety of betamethasonesodium phosphate injection in the treatment of premature birthWANG Qingyu 1 LI Siyu 1 LIU Linfeng 1 LIU Qian 1 ZHONG Qing 1 ZHOU Hongjian2LI Junxia21. School of Pharmaceutical Sciences, Zhengzhou University, Henan, Zhengzhou 450001, China;2. Suicheng Pharmaceutical Co., Ltd., Henan, Xinzheng 451150, China[Abstract] Betamethasone is an isomer of dexamethasone, which has anti-inflammatory, anti-allergic, anti-endotoxin and immunosuppressive functions. Betamethasone sodium phosphate (BSP) injection is a phosphate preparation of betamethasone, which is widely used as a antenatal corticostemids (ACS) drug in clinical practice. There is sufficient evidence for the treatment of premature birth with BSP, and BSP has been included in national guidelines. However, the evidence related to its treatment of premature birth is mainly in high-income countries, and there is less evidence in low to middle-income countries. There is insufficient clinical research on the efficacy and safety of BSP in obstetric applications in China. There are few clinical studies on the direct comparison of efficacy and safety between betamethasone and dexamethasone, and the follow-up study of BSP in treating premature in childhood and adulthood is still insufficient. Further research is needed to provide a decision-making basis for the scientific and rational use of medication in preterm birth.[Key words] Betamethasone sodium phosphate injection; Premature birth; Respiratory distress syndrome; Septicemia; Intraventricular hemorrhage倍他米松磷酸钠（betamethasone sodium phosphate，BSP）是倍他米松的水溶性衍生物，也是地塞米松磷酸钠的16位差向异构体[1]。
二甲双胍片联合德谷门冬胰岛素治疗难治性2型糖尿病的疗效研究
DOI：10.16658/ki.1672-4062.2023.22.092二甲双胍片联合德谷门冬胰岛素治疗难治性2型糖尿病的疗效研究李萌曦，赵忠涛，董焱连云港市赣榆区人民医院内分泌科，江苏连云港222100[摘要]目的探讨二甲双胍片联合德谷门冬胰岛素在难治性2型糖尿病中的诊疗意义。
方法选取2022年6月—2023年6月连云港市赣榆区人民医院接诊的82例难治性2型糖尿病患者为研究对象，采取随机数表法分为两组。
对照组（n=40）采用盐酸二甲双胍片+甘精胰岛素治疗，观察组（n=42）采用盐酸二甲双胍片+德谷门冬双胰岛素治疗。
比较两组患者血糖水平以及血糖波动等相关指标在治疗前后差异和并发症情况。
结果治疗前，两组患者血糖水平比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖均下降，且观察组血糖显著低于对照组，差异有统计学意义（P<0.05）；治疗前，两组患者血糖波动相关指标包括血糖均值、血糖水平标准差、最大血糖波动幅度、餐后血糖波动幅度比较，差异无统计学意义（P>0.05）；治疗后，两组患者血糖波动相关指标均改善，且观察组改善程度显著优于对照组，差异有统计学意义（P<0.05）；观察组并发症发生率低于对照组，差异有统计学意义（P<0.05）。
结论二甲双胍联合德谷门冬双胰岛素治疗效果更好，可明显改善难治性2型糖尿病患者血糖水平。
[关键词] 2型糖尿病；难治性；二甲双胍；德谷门冬双胰岛素[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062（2023）11（b）-0092-04Efficacy of Metformin Tablets Combined with Insulin Degludec and Insu⁃lin Aspart in the Treatment of Refractory Type 2 Diabetes MellitusLI Mengxi, ZHAO Zhongtao, DONG YanDepartment of Endocrinology, Ganyu District People's Hospital, Lianyungang, Jiangsu Province, 222100 China[Abstract] Objective To explore the significance of metformin tablets combined with insulin degludec and insulin as⁃part in the treatment of refractory type 2 diabetes mellitus. Methods A total of 82 patients with refractory type 2 diabe⁃tes mellitus treated in Ganyu District People's Hospital from June 2022 to June 2023 selected as the study objects and divided into two groups by random number table method. The control group (n=40) was treated with metformin hydro⁃chloride tablets + insulin glargine, and the observation group (n=42) was treated with metformin hydrochloride tablets+ Degu asparton double insulin. The differences and complications of blood glucose level, blood glucose fluctuation and other related indicators before and after treatment were compared between the two groups. Results Before treatment, there were no statistically significant differences in blood glucose levels between the two groups of patients (P>0.05). After treatment, blood glucose decreased in both groups, and the degree of blood glucose decrease in the observation group was significantly lower than that in the control group, the differences were statistically significant (P<0.05). Be⁃fore treatment, there were no statistically statistical significance differences in the indexes related to blood glucose fluctuation between the two groups, including mean blood glucose, standard deviation of blood glucose level, largest amplitude of glycemic excursion, and postprandial blood glucose fluctuation (P>0.05). After treatment, the relevant in⁃dexes of blood glucose fluctuation were improved in both groups, and the improvement degree of the observation group was significantly better than that of the control group, the differences were statistically significant (P<0.05). The com⁃plication rate of the observation group was lower than that of the control group, the difference was statistically signifi⁃cant (P<0.05). Conclusion Metformin combined with insulin degludec and insulin aspart is better, can significantly [作者简介]李萌曦（1989-），女，本科，主治医师，研究方向为内分泌科。
甘菊CMO同源基因的分离与表达分析
甘菊CMO同源基因的分离与表达分析牛雅静;王淑慧;黄河;戴思兰【摘要】利用半嵌套巢式PCR结合RACE技术从菊科植物甘菊[Chrysanthemum lavandulifolium(Fisch.ex Trautv.)Makino]中分离得到了一个长度为1 450 bp的片段.序列分析结果表明,其开放阅读框全长1 140bp,编码379个氨基酸残基；在GenBank 比对并进行系统进化分析可知,该片段为CMO同源基因,命名为ClCMO.利用不同胁迫处理进行分析发现,在非胁迫条件下ClCMO基因在甘萄茎、叶、花叶中均有表达信号,在根中没有表达；其可以响应干旱、高盐胁迫和脱落酸(ABA)的诱导,不响应冷热胁迫,并且其表达在水杨酸(SA)诱导下受抑制.这些结果表明,ClCMO基因是提高植物耐干旱、高盐能力的有效基因资源.【期刊名称】《生物技术通报》【年(卷),期】2012(000)004【总页数】5页(P58-62)【关键词】胆碱单加氧酶(CMO);甘氨酸甜菜碱(GB);非生物胁迫;表达;甘菊【作者】牛雅静;王淑慧;黄河;戴思兰【作者单位】北京林业大学园林学院,北京100083;北京林业大学园林学院,北京100083;北京林业大学园林学院,北京100083;北京林业大学园林学院,北京100083【正文语种】中文渗透胁迫（osmotic stress）是植物生长发育过程中所面临的最主要胁迫之一，脯氨酸、山梨醇、海藻糖和甜菜碱等渗透调节物质在植物抵御渗透胁迫中起到了重要的作用。
甘氨酸甜菜碱（glycine betaine，GB）是甜菜碱的一种，是植物中广泛存在的一类渗透调节物质，它主要通过两步酶促反应合成：首先是由胆碱（choline）在胆碱单加氧酶（choline monooxygenase，CMO）的催化下生成甜菜碱醛（betaine aldehyde）[1]，随后甜菜碱醛在甜菜碱醛脱氢酶（betaine aldehyde dehydragensase，BADH）的催化下合成甘氨酸甜菜碱[2]。